Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$9.45M | -$13.6M | -$13.3M | -$14.2M | -$15.3M | -$24.1M | -$28.8M | -$39.0M | -$51.8M | -$23.0M |
| Net income | -$6.18M | -$13.6M | -$13.2M | -$14.1M | -$15.1M | -$24.1M | -$28.6M | -$42.8M | -$44.6M | -$21.8M |
| EPS (diluted) | -$2.14 | -$10.70 | -$5.23 | -$1.84 | -$1.84 | -$4.35 | -$4.05 | -$3.50 | -$41.89 | -$8.35 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.28M | -$11.0M | -$11.4M | -$11.7M | -$13.9M | -$22.6M | -$25.2M | -$32.4M | -$47.6M | -$23.1M |
| Capital expenditures | $72.3K | $347K | $385K | $24.5K | $62.4K | $141K | $226K | $864K | $104K | $5.88K |
| Free cash flow | -$8.35M | -$11.4M | -$11.8M | -$11.7M | -$14.0M | -$22.7M | -$25.4M | -$33.2M | -$47.7M | -$23.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.4M | $10.0M | $13.3M | $10.6M | $57.2M | $35.7M | $19.9M | $9.56M | $23.3M | $13.2M |
| Total assets | $15.3M | $12.9M | $15.1M | $12.3M | $58.7M | $37.2M | $21.6M | $12.1M | $25.5M | $15.0M |
| Total liabilities | $1.78M | $2.12M | $1.79M | $3.19M | $3.86M | $4.16M | $6.08M | $25.9M | $9.80M | $5.06M |
| Shareholders' equity | $13.5M | $10.8M | $13.3M | $9.06M | $54.8M | $33.0M | $8.15M | -$15.2M | $14.3M | $8.54M |
| Retained earnings | -$70.8M | -$84.3M | -$97.6M | -$112M | -$127M | -$151M | -$179M | -$203M | -$247M | -$269M |
| Shares (wtd avg diluted) | 10.4M | 1.67M | 4.73M | 9.39M | 19.8M | 5.55M | 7.06M | 12.2M | 1.24M | 2.61M |
Every figure is extracted from Cellectar Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.